Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Uppsala – page 24

335 clinical trials in Uppsala, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Uppsala at a glance
335
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

335 trials in Uppsala

Open in trial search

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Chronic lymphocytic leukaemia

Not recruiting

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effects of Metoprolol Tartrate for Patients with Chronic Obstructive Pulmonary Disease (COPD) Without Cardiovascular Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Metoprolol Tartrate
  • Sponsor:Region Oerebro Laen

C3 glomerulopathy

Not recruiting

Study Comparing Aliskiren and Enalapril for Patients with C3 Glomerulopathy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Aliskiren
  • Sponsor:Region Skane

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Diffuse large B-cell lymphoma+2

Not recruiting

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Dementia Alzheimer's type+1

Not recruiting

Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer's Disease: Testing Safety and Effectiveness Over 18 Months

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lecanemab
  • Sponsor:Eisai Limited

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Obesity+1

Not recruiting

Study on the Safety and Effects of AZD9550 for Overweight and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) with or without Type 2 Diabetes

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:AstraZeneca AB

Magnetic resonance imaging+1

Not recruiting

Study Comparing Gadoquatrane with Gadoteric Acid, Gadobutrol, and Gadoteridol for MRI in Adults with Brain or Spinal Cord Issues

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Uppsala

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic breast cancer and prostate cancer treatments, including targeted therapies and novel drug combinations.

  • Advanced breast cancer treatments
  • Prostate cancer therapies
  • Colorectal cancer studies

Particular emphasis on HER2-positive breast cancer imaging and treatment optimization.

02 Metabolic Disorders

Research initiatives targeting obesity management and metabolic health, with studies evaluating new therapeutic approaches for weight management in both adults and adolescents.

  • Weight management treatments
  • Adolescent obesity studies
  • Metabolic health interventions

Focus on innovative drug combinations and long-term effectiveness studies.

03 Cardiovascular and Renal Studies

Comprehensive research on heart failure prevention and chronic kidney disease management, investigating new therapeutic combinations.

  • Heart failure prevention
  • Kidney disease treatments
  • Hypertension management

Emphasis on combination therapies and preventive approaches.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.